We are live on
!
Find out more
B
Bailard Portfolio holdings
AUM
$4.35B
1-Year Est. Return
23.57%
This Fund
S&P 500
This Quarter
Est. Return
+21.05%
1 Year Est. Return
+23.57%
3 Year Est. Return
+74.84%
5 Year Est. Return
+96.64%
10 Year Est. Return
+374.16%
AUM
$1.79B
AUM Growth
+$386M
(+27%)
Cap. Flow
+$121M
Cap. Flow
% of AUM
6.74%
Top 10 Holdings %
Top 10 Hldgs %
33.84%
Holding
575
New
129
Increased
174
Reduced
152
Closed
75
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$47.2M |
| 2 |
iShares Core MSCI EAFE ETF
IEFA
|
+$39.6M |
| 3 |
iShares National Muni Bond ETF
MUB
|
+$10.5M |
| 4 |
L3Harris
LHX
|
+$4.57M |
| 5 |
Vanguard Small-Cap Value ETF
VBR
|
+$4.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares S&P Small-Cap 600 Value ETF
IJS
|
+$5.36M |
| 2 |
State Street SPDR Nuveen ICE Municipal Bond ETF
TFI
|
+$4.62M |
| 3 |
Gilead Sciences
GILD
|
+$4.55M |
| 4 |
Vanguard Total Stock Market ETF
VTI
|
+$4.16M |
| 5 |
Meta Platforms (Facebook)
META
|
+$4.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.8% |
| 2 | Healthcare | 8.12% |
| 3 | Financials | 4.94% |
| 4 | Communication Services | 4.63% |
| 5 | Consumer Discretionary | 4.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Starbucks
SBUX
$118B
| $5.06M | 0.28% |
68,801
+617
| +0.9% | +$46.4K |
|
|
ESPR
77
DELISTED
Esperion Therapeutics
ESPR
| $5.05M | 0.28% |
98,500
+5,200
| +6% | +$218K |
|
78
Bank of America
BAC
$430B
| $4.88M | 0.27% |
205,441
+40,357
| +24% | +$954K |
|
79
CVS Health
CVS
$136B
| $4.8M | 0.27% |
73,897
+6,457
| +10% | +$407K |
|
80
PNC Financial Services
PNC
$99.5B
| $4.78M | 0.27% |
45,448
+2,332
| +5% | +$246K |
|
81
Cummins
CMI
$91.8B
| $4.63M | 0.26% |
26,720
+2,381
| +10% | +$381K |
|
82
Sprott Physical Gold
PHYS
$14.6B
| $4.54M | 0.25% |
317,359
| – | – |
|
83
Quest Diagnostics
DGX
$25.2B
| $4.48M | 0.25% |
39,291
+3,995
| +11% | +$424K |
|
|
MRSN
84
DELISTED
Mersana Therapeutics
MRSN
| $4.47M | 0.25% |
7,640
+1,840
| +32% | +$628K |
|
85
iShares Global REIT ETF
REET
$5.03B
| $4.3M | 0.24% |
205,873
+104,955
| +104% | +$2.12M |
|
86
Qualcomm
QCOM
$180B
| $4.17M | 0.23% |
45,733
+5,677
| +14% | +$455K |
|
|
87
L3Harris
LHX
$55.8B
| $4.12M | 0.23% |
+24,296
| New | +$4.57M |
|
88
Linde
LIN
$234B
| $4.09M | 0.23% |
19,299
+1,622
| +9% | +$313K |
|
89
Teva Pharmaceuticals
TEVA
$36.3B
| $4.09M | 0.23% |
+332,000
| New | +$3.75M |
|
90
Lam Research
LRCX
$400B
| $4.04M | 0.23% |
124,980
+17,660
| +16% | +$482K |
|
91
Vanguard Consumer Staples ETF
VDC
$7.78B
| $3.94M | 0.22% |
26,328
-3,497
| -12% | -$518K |
|
92
Booz Allen Hamilton
BAH
$7.9B
| $3.89M | 0.22% |
49,949
+13,549
| +37% | +$1.02M |
|
93
ASML
ASML
$693B
| $3.73M | 0.21% |
10,126
+2,980
| +42% | +$935K |
|
|
SGMO
94
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $3.63M | 0.2% |
405,000
-46,000
| -10% | -$427K |
|
|
ITCI
95
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.62M | 0.2% |
+141,000
| New | +$2.85M |
|
96
iShares MSCI EAFE ETF
EFA
$76.1B
| $3.57M | 0.2% |
58,707
+6,084
| +12% | +$352K |
|
97
Trane Technologies
TT
$106B
| $3.52M | 0.2% |
39,536
+973
| +3% | +$84.6K |
|
98
iShares S&P 500 Value ETF
IVE
$48.5B
| $3.47M | 0.19% |
32,055
+752
| +2% | +$79.8K |
|
99
iShares S&P 500 Growth ETF
IVW
$72.9B
| $3.47M | 0.19% |
66,836
-240
| -0.4% | -$11.5K |
|
100
Sony
SONY
$122B
| $3.47M | 0.19% |
250,685
+535
| +0.2% | +$6.95K |
|
Similar funds
EC
SFM
NHC
EQF
NEI
MYIA
Bailard's Q2 2020 Portfolio in Review
As of Q2 2020, Bailard held 575 positions worth $1.79B, up 27% from $1.4B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Bailard deployed $121M of net new capital in Q2 2020, opening 129 new positions and adding to 174 existing holdings. Its largest new stake was L3Harris: 24,296 shares worth $4.12M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was iShares S&P Small-Cap 600 Value ETF, an estimated $5.36M trimmed.
- Bailard's largest Q2 2020 buy was L3Harris: 24,296 shares worth $4.12M.
- Bailard added most to State Street SPDR S&P 500 ETF Trust in Q2 2020, an estimated $47.2M increase.
- Bailard's biggest Q2 2020 reduction was iShares S&P Small-Cap 600 Value ETF, cutting an estimated $5.36M.
- Bailard fully exited Voyager Therapeutics in Q2 2020, selling an estimated $1.29M.
- Bailard's ten largest holdings make up 34% of its $1.79B portfolio in Q2 2020.
- Bailard opened 129 new positions and closed 75 in Q2 2020.
- Bailard's portfolio value rose 27% quarter-over-quarter to $1.79B.
Based on Bailard's 13F filing for Q2 2020, filed 12 Aug 2020.